Skip to content
Biodatica
Start free

Ajax Therapeutics, Inc.

Palo Alto, California

OncologyPhase II
Compare Sign in to watch

What changed

Phase I trial registered: A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

2mo agoTrial registeredMay 12, 2026Source filing (opens the source filing in a new tab)

Momentum

94no change

Momentum 94 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,843 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    May 4, 2026

    Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · NOT_YET_RECRUITING · sponsor: John Mascarenhas · Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

    ClinicalTrials.gov · NCT07447817 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Jan 2, 2026

    Relapsed Acute Myeloid Leukemia · RECRUITING · sponsor: Douglas Tremblay · Imetelstat Combinations in Relapsed AML

    ClinicalTrials.gov · NCT07320235 (opens the source filing in a new tab)

  3. Trial

    EARLY_PHASE1 registered

    Aug 25, 2025

    Myelofibrosis，MF · RECRUITING · sponsor: University of Kansas Medical Center · Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

    ClinicalTrials.gov · NCT06414681 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Oct 23, 2024

    Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, PMF, PPV-MF, PET-MF · RECRUITING · sponsor: Ajax Therapeutics, Inc. · A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

    ClinicalTrials.gov · NCT06343805 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Aug 2, 2022

    Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF · ACTIVE_NOT_RECRUITING · sponsor: John Mascarenhas · Study of Canakinumab in Patients With Myelofibrosis

    ClinicalTrials.gov · NCT05467800 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources